Key Highlights
- Ken Griffin’s hedge fund Citadel expanded its Eli Lilly stake by nearly 400% during Q2, acquiring 704,000 more shares
- The fund now owns 945,000 shares of LLY valued at $1.18 billion, representing its sixth-biggest holding
- Shares have climbed 17% this year and touched record highs in recent trading sessions
- The pharmaceutical giant debuted Foundayo, its oral weight-loss medication, in Britain—the first European nation to offer it
- Analyst consensus points to Strong Buy with a target price of $1,375.78
Shares of Eli Lilly are currently trading near $1,228, marking a 17% gain year-to-date, following a substantial increase in Ken Griffin’s Citadel position during the second quarter of 2026.
During Q2, Citadel accumulated 704,000 more LLY shares, expanding its total ownership to 945,000 shares with a market value of $1.18 billion. This positions Eli Lilly as the sixth-most significant holding in Citadel’s portfolio, which spans roughly 7,500 different equities.
The hedge fund seems to have capitalized on a market downturn. Eli Lilly shares had declined 21% year-to-date by late April before staging a recovery. Griffin’s team built up their position during the second quarter, and the stock has rallied significantly afterward.
The stock’s weakness aligned with U.S. regulatory clearance for Foundayo, Eli Lilly’s pill-form weight-loss treatment. Since then, shares have rebounded strongly and recorded fresh all-time highs recently.
The company’s portfolio of diabetes and weight management medications continues to perform exceptionally well. Revenue from these products combined is projected to surpass $55 billion in the current year.
British Launch for Foundayo
This Monday, Eli Lilly introduced Foundayo to the United Kingdom market, establishing the UK as Europe’s inaugural country to provide this oral GLP-1 therapy. The medication, scientifically identified as orforglipron, can now be obtained through private prescriptions.
UK health authorities granted authorization for Foundayo on August 10. The drug represents the second GLP-1 tablet accessible to British patients, after Novo Nordisk’s Wegovy pill.
Monthly costs for Foundayo in the United Kingdom are anticipated to range from £100 to £120. This pricing sits well below Lilly’s injectable Mounjaro, which carries a £330 monthly price tag.
By comparison, the Wegovy pill in private UK markets runs from £74 to £129 monthly, varying by dosage strength and subscription arrangement.
Before NHS availability can proceed, England’s National Institute for Health and Care Excellence (NICE) must finalize its assessment. NICE has asked for additional data after its initial committee session, with no timeline established for a follow-up evaluation.
Analyst Outlook for LLY
Currently, 20 Wall Street analysts provide coverage on LLY, with the overall rating standing at Strong Buy. This assessment is based on 18 Buy ratings and two Hold ratings published in the last three months.
The mean price target stands at $1,375.78, suggesting approximately 12% potential appreciation from present trading levels.
European Union regulators continue evaluating Foundayo. Novo Nordisk’s Wegovy pill has secured favorable guidance from the European Medicines Agency, though the European Commission’s conclusive ruling remains outstanding.
Within the United States, direct-pay costs for Foundayo begin at $149 monthly and can climb to $349 for stronger dosages. A recently launched Medicare pilot initiative provides limited access at $50 per month.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
